1,418,489 Shares in CymaBay Therapeutics Inc (CBAY) Acquired by Great Point Partners LLC

Great Point Partners LLC purchased a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,418,489 shares of the biopharmaceutical company’s stock, valued at approximately $11,164,000. CymaBay Therapeutics comprises 1.4% of Great Point Partners LLC’s investment portfolio, making the stock its 21st biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in the company. PNC Financial Services Group Inc. increased its stake in shares of CymaBay Therapeutics by 23.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,120 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,460 shares during the last quarter. Bank of America Corp DE increased its stake in shares of CymaBay Therapeutics by 1.5% during the 4th quarter. Bank of America Corp DE now owns 164,192 shares of the biopharmaceutical company’s stock worth $1,291,000 after purchasing an additional 2,478 shares during the last quarter. Citigroup Inc. increased its stake in shares of CymaBay Therapeutics by 17.7% during the 4th quarter. Citigroup Inc. now owns 19,966 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 3,000 shares during the last quarter. Raymond James & Associates grew its stake in CymaBay Therapeutics by 7.7% in the 4th quarter. Raymond James & Associates now owns 82,205 shares of the biopharmaceutical company’s stock valued at $647,000 after buying an additional 5,899 shares during the last quarter. Finally, Weiss Multi Strategy Advisers LLC grew its stake in CymaBay Therapeutics by 12.6% in the 4th quarter. Weiss Multi Strategy Advisers LLC now owns 62,000 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 6,936 shares during the last quarter. Institutional investors own 97.90% of the company’s stock.

NASDAQ:CBAY opened at $11.93 on Friday. CymaBay Therapeutics Inc has a 1 year low of $6.31 and a 1 year high of $15.00. The firm has a market capitalization of $768.36 million, a P/E ratio of -9.47 and a beta of 1.82.

In related news, Director Carl Goldfischer sold 11,675 shares of the firm’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $9.02, for a total value of $105,308.50. Following the transaction, the director now directly owns 2,335 shares in the company, valued at approximately $21,061.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company’s stock.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of CymaBay Therapeutics in a research note on Friday, November 23rd. Svb Leerink reiterated an “outperform” rating on shares of CymaBay Therapeutics in a research note on Thursday, February 21st. Zacks Investment Research lowered shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. ValuEngine lowered shares of CymaBay Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 24th. Finally, BidaskClub upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, February 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $19.13.

ILLEGAL ACTIVITY NOTICE: “1,418,489 Shares in CymaBay Therapeutics Inc (CBAY) Acquired by Great Point Partners LLC” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2019/03/23/1418489-shares-in-cymabay-therapeutics-inc-cbay-acquired-by-great-point-partners-llc.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Recommended Story: What is systematic risk?

Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.